ArticleAmerican journal of translational research2019
Article in American journal of translational research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.
- Treatment Response, Survival, and Safety of Transarterial Chemoembolization With CalliSpheresFrontiers in oncology · 2021Pooled it
- Iodinated Cyanoacrylate-Based Novel Liquid Embolic Compositions with Inherent Radiopacity for Endovascular Embolization.Advanced healthcare materials · 2024Article
- Clinical research progress of callisperesDiscover oncology · 2024Review
- Article
- Transarterial chemoembolization of unresectable renal cell carcinoma with doxorubicin-loaded CalliSpheres drug-eluting beads.Scientific reports · 2022Article
- Callispheres drug-eluting bead transhepatic artery chemoembolization with oral delivery of sorafenib for the treatment of unresectable liver cancer.Frontiers in surgery · 2022Article
- Assessment of efficacy and safety by CalliSpheres versus HepaSpheres for drug-eluting bead transarterial chemoembolization in unresectable large hepatocellular carcinoma patients.Drug delivery · 2021Article
- Clinical effect of bronchial arterial infusion chemotherapy and CalliSpheres drug-eluting beads in patients with stage II-IV lung cancer: A prospective cohort study.Thoracic cancer · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to evaluate the operational performance, embolization effect and safety of CalliSpheres microspheres (CSM) in a porcine renal model. 24 healthy normal pigs were randomized into CSM group and Embosphere microspheres (ESM) group equally, and embolized with CSM or ESM in the lower pole of right kidneys, respectively. On D2, D7 and D28 after the operation, angiography and biochemistry examination were performed, and then the pigs were subjected to renal macroscopic and histopathological examination after euthanasia (4 pigs/group per each time point). The embolization was performed successfully in all pigs without obvious adverse events or deaths, and there was no difference in operation assessments (including number of embolized arteries, volume of injected microspheres and vessel recanalization rate) between CSM group and ESM group. After the operation, all pigs in CSM group and ESM group presented with renal necrosis, stasis and capsule exudation on D2 and D7, and capsule thickening, fibrosis and renal atrophy on D28, and there was no difference in these macroscopic or microscopic manifestations between two groups. For biochemistry indexes (including blood routine, coagulation function, liver function and renal function), most of them were similar between two groups at each time point. CSM embolizes porcine renal artery effectively and safely without obvious adverse events or deaths, which might be a good option for embolization therapy in clinical practices.
Indexed as
Identifiers
31396326PMC6684889W3022552033What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.